Oxford, UK – 13 September 2010. Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, today announced that it has been certified compliant with ISO/IEC 27001:2005, an international information security management standard. Extending to all data generation and security procedures, including OGT’s CytoSure™ and Genefficiency™ services, biomarker discovery solutions, and the development of CytoSure Interpret Software, this certification acknowledges that data confidentiality, availability and integrity is carefully managed and controlled.
Building on the ISO 9001:2008 registration earlier this year, OGT’s new ISO/IEC 27001:2005 certification provides clear evidence of robust information security to meet all customer needs. Dr Mike Evans, OGT’s CEO, commented: “Being one of only 448 companies within the UK to be compliant with ISO/IEC 27001:2005 demonstrates our ongoing commitment to information security and confidentiality. It also emphasises the dedication and reliability of our team to provide high-quality products and services, while protecting the integrity and confidentiality of all information and data.”
The ISO/IEC 27001:2005 certification was awarded following an assessment by the British Standards Institution (BSI). For further information on OGT’s products and services, please visit www.ogt.co.uk.
For further information, please contact: Oxford Gene Technology, Begbroke Science Park, Sandy Lane, Yarnton, Oxford OX5 1PF T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684 ; E: products@ogt.co.uk W: www.ogt.co.uk Notes for editors:
About Oxford Gene Technology
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative clinical genetics and diagnostic solutions to advance molecular medicine. www.ogt.co.uk.
Clinical & Genomic Solutions: OGT’s Genefficiency™ service is a unique combination of world-leading platforms, people, processing power and performance synchronised to deliver rapid, high quality genomic data to customers worldwide. The OGT CytoSure™ cytogenetics array, labelling and interpretation software products provide a complete solution for the detection of chromosomal abnormalities. Together, Genefficiency and CytoSure offer a unique, standardised and integrated solution for cytogenetics research.
Biomarker Discovery: OGT has a proven pedigree in genomic technology, which, together with the experience gained through the purchase of Sense Proteomics in 2009, enables OGT to develop highly specific customised genomic and proteomic biomarker panels for cancer and other diseases. OGT develops these for clinical screening and companion diagnostics requirements, both for direct sale and also for collaboration with partner companies.
CytoSure™: For research use only This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.
